MediBeacon

MediBeacon is a medical technology company headquartered in St. Louis, Missouri, United States. The company is developing a platform that combines fluorescent tracer agents with transdermal detection technology to enable physiological monitoring. According to its website, the core idea is to use bright fluorescent agents designed not to interact with the body, which are then sensed through the skin. This approach aims to measure and monitor vital organ function and disease progression. The company's activities span both clinical and preclinical applications. Its R&D platform is focused on new clinical applications for fluorescent tracer agent-based systems. Clinical and preclinical studies are underway to advance the use of fluorescence for measuring and monitoring disease progression. MediBeacon also maintains a patent estate covering composition of matter, device, algorithm, process, and method patents in the United States, Europe, and globally. MediBeacon serves leading academic centers, research institutes, contract research organizations, and pharmaceutical companies worldwide that rely on its technology for preclinical research. The company provides exclusive preclinical content for researchers through a registration process on its website. Its stated goal is to develop clinically practical solutions that can reduce the cost of healthcare while improving the standard of care. The company is privately held and operates globally, with a focus on advancing fluorescence-based monitoring solutions.

MediBeacon is a privately held medical technology company based in St. Louis, Missouri, United States. The company was founded to develop a novel platform for physiological monitoring that combines fluorescent tracer agents with transdermal detection technology. The core concept involves using bright fluorescent agents engineered not to interact with the body, which are then sensed through the skin to measure and monitor vital organ function and disease progression. From its inception, MediBeacon has focused on both clinical and preclinical applications. Its R&D platform is dedicated to developing new clinical applications for fluorescent tracer agent-based systems. Clinical and preclinical studies are underway to advance the use of fluorescence for measuring and monitoring disease progression. The company has built a patent estate covering composition of matter, device, algorithm, process, and method patents in the United States, Europe, and globally. MediBeacon's technology is used by leading academic centers, research institutes, contract research organizations, and pharmaceutical companies worldwide for preclinical research. The company provides exclusive preclinical content to researchers through a registration process on its website. Its stated goal is to develop clinically practical solutions that can reduce the cost of healthcare while improving the standard of care. While the exact founding date and founders are not specified in the available evidence, the company is known to be headquartered in St. Louis, Missouri, as indicated by Wikidata. MediBeacon continues to operate as a private company, advancing its fluorescence-based monitoring platform.

Developer of fluorescence-based physiological monitoring solutions for clinical and preclinical applications.

• Fluorescent tracer agents

  Bright fluorescent agents designed not to interact with the body, used for physiological monitoring.

• Transdermal detection technology

  Technology that senses fluorescent agents through the skin.

1. 1MediBeacon Official Websitemedibeacon.com
2. 2MediBeacon Historymedibeacon.com
3. 3MediBeacon Peoplemedibeacon.com
4. 4Wikidata: Medibeaconwikidata.org